Sprouty4 is epigenetically upregulated in human colorectal cancer

References

• Felfly H, Klein OD. Sprouty genes regulate proliferation and survival of human embryonic stem cells. Sci Rep. 2013;3(1):2277.
   PubMedGoogle Scholar
• Kousa YA, Roushangar R, Patel N, et al. IRF6 and SPRY4 signaling interact in periderm development. J Dent Res. 2017;96(11):1306–12.
   PubMed Web of Science ®Google Scholar
• Katoh Y, Katoh M. FGF signaling inhibitor, SPRY4, is evolutionarily conserved target of WNT signaling pathway in progenitor cells. Int J Mol Med. 2006;17(3):529–532.
   PubMed Web of Science ®Google Scholar
• Celik-Selvi BE, Stütz A, Mayer C-E, et al. Sprouty3 and sprouty4, two members of a family known to inhibit FGF-mediated signaling, exert opposing roles on proliferation and migration of glioblastoma-derived cells. Cells. 2019;8(8):808.
   PubMed Web of Science ®Google Scholar
• Li M, Zhang H, Zhao X, et al. SPRY4-mediated ERK1/2 signaling inhibition abolishes 17β-estradiol-induced cell growth in endometrial adenocarcinoma cell. Gynecological Endocrinol. 2014;30(8):600–604.
   PubMed Web of Science ®Google Scholar
• Qiu B, Chen T, Sun R, et al. Sprouty4 correlates with favorable prognosis in perihilar cholangiocarcinoma by blocking the FGFR-ERK signaling pathway and arresting the cell cycle. eBioMedicine. 2019;50:166–177.
   PubMed Web of Science ®Google Scholar
• Jing H, Liaw L, Friesel R, et al. Suppression of Spry4 enhances cancer stem cell properties of human MDA-MB-231 breast carcinoma cells. Cancer Cell Int. 2016;16(1):19.
   PubMedGoogle Scholar
• Shaverdashvili K, Zhang K, Osman I, et al. MT1-MMP dependent repression of the tumor suppressor SPRY4 contributes to MT1-MMP driven melanoma cell motility. Oncotarget. 2015;6(32):33512–33522.
   PubMedGoogle Scholar
• Wang J, Thompson B, Ren C, et al. Sprouty4, a suppressor of tumor cell motility, is downregulated by DNA methylation in human prostate cancer. Prostate. 2006;66(6):613–624.
   PubMed Web of Science ®Google Scholar
• Masoumi-Moghaddam S, Amini A, Wei A-Q, et al. Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer. Int J Cancer. 2015;137(3):560–570.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang H, Liu X, et al. Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP. Oncogene. 2019;38(11):1892–1904.
   PubMed Web of Science ®Google Scholar
• Kayser S, Feszler M, Krzykalla J, et al. Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients. Eur J Haematol. 2017;99(6):544–552.
   PubMed Web of Science ®Google Scholar
• Zhou X, Xie S, Yuan C, et al. Lower expression of SPRY4 predicts a poor prognosis and regulates cell proliferation in colorectal cancer. Cell Physiol Biochem. 2016;40(6):1433–1442.
   PubMedGoogle Scholar
• Gromova P, Ralea S, Lefort A, et al. Kit K641E oncogene up-regulates Sprouty homolog 4 and trophoblast glycoprotein in interstitial cells of Cajal in a murine model of gastrointestinal stromal tumours. J Cell Mol Med. 2009;13(8a):1536–1548.
   PubMed Web of Science ®Google Scholar
• Atay S, Wilkey DW, Milhem M, et al. Insights into the proteome of gastrointestinal stromal tumors-derived exosomes reveals new potential diagnostic biomarkers. Mol Cell Proteomics. 2018;17(3):495–515. PubMed PMID: 29242380.
   PubMed Web of Science ®Google Scholar
• Tennis MA, Van Scoyk MM, Freeman SV, et al. Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARγ in non–small cell lung cancer. Mol Cancer Res. 2010;8(6):833.
   PubMed Web of Science ®Google Scholar
• Stütz A, Kamptner AZM, Sutterlüty H. A sprouty4 mutation identified in kallmann syndrome increases the inhibitory potency of the protein towards FGF and connected processes. Int J Mol Sci. 2021;22(4):2145.
   PubMed Web of Science ®Google Scholar
• Marques IJ, Gomes I, Pojo M, et al. Identification of SPRY4 as a novel candidate susceptibility gene for familial nonmedullary thyroid cancer. Thyroid. 2021;31(9):1366–1375.
   PubMed Web of Science ®Google Scholar
• Bikkavilli RK, Zerayesus SA, Van Scoyk M, et al. K-homology splicing regulatory protein (KSRP) promotes post-transcriptional destabilization of Spry4 transcripts in non-small cell lung cancer. J Biol Chem. 2017;292(18):7423–7434.
   PubMed Web of Science ®Google Scholar
• Tong C-W, Wang J-L, Jiang M-S, et al. Novel genes that mediate nuclear respiratory factor 1-regualted neurite outgrowth in neuroblastoma IMR-32 cells. Gene. 2013;515(1):62–70.
   PubMed Web of Science ®Google Scholar
• Doriguzzi A, Haigl B, Gsur A, et al. The increased Sprouty4 expression in response to serum is transcriptionally controlled by Specific protein 1. Int J Biochem Cell Biol. 2015;64:220–228.
   PubMed Web of Science ®Google Scholar
• Plotnik JP, Budka JA, Ferris MW, et al. ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells. Nucleic Acids Res. 2014;42(19):11928–11940.
   PubMed Web of Science ®Google Scholar
• Sun M, Huang F, Yu D, et al. Autoregulatory loop between TGF-β1/miR-411-5p/SPRY4 and MAPK pathway in rhabdomyosarcoma modulates proliferation and differentiation. Cell Death Dis. 2015;6(8):e1859–e.
   PubMedGoogle Scholar
• Chai Z, Fan H, Li Y, et al. miR-1908 as a novel prognosis marker of glioma via promoting malignant phenotype and modulating SPRY4/RAF1 axis. Oncol Rep. 2017;38(5):2717–2726.
   PubMed Web of Science ®Google Scholar
• Tian Y, Fu X, Li Q, et al. MicroRNA‑181 serves an oncogenic role in breast cancer via the inhibition of SPRY4. Mol Med Rep. 2018;18(6):5603–5613. PubMed PMID: 30365052.
   PubMed Web of Science ®Google Scholar
• Ma Q, Xu Q, Zhao J, et al. Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance. Cancer Lett. 2021;520:243–254.
   PubMed Web of Science ®Google Scholar
• Mirabello L, Kratz CP, Savage SA, et al. Promoter methylation of candidate genes associated with familial testicular cancer. Int J Mol Epidemiol Genet. 2012;3(3):213–227. PubMed PMID: 23050052.
   PubMedGoogle Scholar
• Mustafi R, Dougherty U, Mustafi D, et al. ADAM17 is a tumor promoter and therapeutic target in western diet-associated colon cancer. Clin Cancer Res. 2017;23(2):549–561. PubMed PMID: 27489286.
   PubMedGoogle Scholar
• Seidelin JB, Horn T, Nielsen OH. Simple and efficient method for isolation and cultivation of endoscopically obtained human colonocytes. Am J Physiol Gastrointest Liver Physiol. 2003;285(6):G1122–G8.
   PubMed Web of Science ®Google Scholar
• Khalil H, Nie W, Edwards RA, et al. Isolation of primary myofibroblasts from mouse and human colon tissue. J Vis Exp. 2013;80:50611. PubMed PMID: 24145735.
   Google Scholar
• Khare S, Wilson DM, Tien XY, et al. 1,25-Dihydroxycholecalciferol rapidly activates rat colonic particulate guanylate cyclase via a protein kinase C-dependent mechanism. Endocrinology. 1993;133(5):2213–2219.
   PubMed Web of Science ®Google Scholar
• L-C L, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427–1431.
   PubMed Web of Science ®Google Scholar
• Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997;25(12):2532–2534. PubMed PMID: 9171110.
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol. 2015;19(1A):A68–A77. PubMed PMID: 25691825.
   Google Scholar
• Seaborn.Pydata.org. Seaborn: statistical data visualization-Seaborn 0.9.0 documentation, 2018. Available online: http://seaborn.pydata.org/. cited 2021 Apr 15.
   Google Scholar
• Rosenbloom KR, Sloan CA, Malladi VS, et al. ENCODE data in the UCSC genome browser: year 5 update. Nucleic Acids Res. 2013;41(1):D56–D63. PubMed PMID: 23193274.
   PubMedGoogle Scholar
• Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71–e. PubMed PMID: 26704973.
   PubMed Web of Science ®Google Scholar
• Mermel CH, Schumacher SE, Hill B, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4):R41.
   PubMed Web of Science ®Google Scholar
• Li W, Zhang X, Lu X, et al. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res. 2017;27(10):1243–1257. PubMed PMID: 28925386.
   PubMed Web of Science ®Google Scholar
• Ding W, Chen J, Feng G, et al. DNMIVD: DNA methylation interactive visualization database. Nucleic Acids Res. 2020;48(D1):D856–D62. PubMed PMID: 31598709.
   PubMed Web of Science ®Google Scholar
• Guo K, Zhu H, Li Q, et al. SPRY4 suppresses proliferation and induces apoptosis of colorectal cancer cells by repressing oncogene EZH2. Aging (Albany NY). 2021;13(8):11665–11677.
   PubMedGoogle Scholar
• Stuckel AJ, Zhang W, Zhang X, et al. Enhanced CXCR4 expression associates with increased gene body 5-hydroxymethylcytosine modification but not decreased promoter methylation in colorectal cancer. Cancers (Basel). 2020;12(3):539.
   PubMed Web of Science ®Google Scholar
• Stuckel AJ, Zeng S, Lyu Z, et al. Epigenetic DNA modifications upregulate SPRY2 in human colorectal cancers. Cells. 2021;10(10):2632.
   PubMed Web of Science ®Google Scholar
• Jiang J, Liu L-Y. Zinc finger protein X-linked is overexpressed in colorectal cancer and is associated with poor prognosis. Oncol Lett. 2015;10(2):810–814. PubMed PMID: 26622575.
   PubMed Web of Science ®Google Scholar
• Rhie SK, Yao L, Luo Z, et al. ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream of transcription start sites at the majority of CpG island promoters. Genome Res. 2018;28(3):310–320. PubMed PMID: 29429977.
   PubMed Web of Science ®Google Scholar
• Schumacher MA, Hsieh JJ, Liu CY, et al. Sprouty2 limits intestinal tuft and goblet cell numbers through GSK3β-mediated restriction of epithelial IL-33. Nat Commun. 2021;12(1):1–6.
   PubMed Web of Science ®Google Scholar
• Chen K, Zhang J, Guo Z, et al. Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer. Cell Res. 2016;26(1):103–118.
   PubMed Web of Science ®Google Scholar
• Yang X, Han H, De Carvalho Daniel D, et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell. 2014;26(4):577–590.
   PubMed Web of Science ®Google Scholar